6 | Himalaya Livline | Vol 6 | No. 5 | Sep–Dec 2023 Liv.52® Drops in the Management of Loss of Appetite in Children An excerpt of a clinical study conducted by Bhattacharya SS et al published in the journal The Antiseptic has been featured here. Aim To evaluate the safety and efficacy of Liv.52 Drops in the management of loss of appetite in children. Materials and Methods This open clinical trial included 70 children of either sex with a history of loss of appetite for at least 1 month. The parents were instructed to administer Liv.52 Drops orally to their children at a dosage of 15 to 20 drops, BID, for 12 weeks. The children were evaluated for appetite, nausea, and fatigue every fortnight for 3 months. Their body weight and height were also noted. All children were subjected to detailed clinical and hematological examinations and liver function tests (serum bilirubin and alanine transaminase) at entry and at the end of the study period. The primary end point was the subjective decrease in loss of appetite leading to an increase in body weight. The secondary end points were general well-being and the incidence of adverse effects, if any. Results Of the 70 children enrolled, 67 children completed the study. Most children showed significant improvement in appetite at the end of 3 months of the treatment with Liv.52 Drops (P < .01). Of the 67 children, only 6 had loss of appetite at the end of the study. Only 7 of the 30 children who reported to have nausea at entry, still had nausea at the end of the study (P < .01). Weight loss was noticed in 60 children at entry, and there was a significant weight gain at the end of every month (P < .01) in all except 5 children (Figure). The children experienced less fatigue after the treatment. There was a significant improvement in hemoglobin and serum protein levels (P < .01). There were no adverse effects reported. Conclusion These findings suggest that Liv.52 Drops are safe and effective in managing loss of appetite in children. Figure. Effect of Liv.52 Drops on Clinical Parameters of Growth in Children With Loss of Appetite aP < .05 compared with the at-entry values. 0 10 30 40 20 50 60 70 No. of Patients Loss of Appetite Weight Loss Vomiting/Nausea Baseline a a a a a a a a a At 1 month At 2 months At 3 months Research at Himalaya
RkJQdWJsaXNoZXIy MjAwNDg=